MI22-00013, NCT06273020: Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke |
|
|
| Recruiting | 4 | 60 | RoW | Cerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysin | Hospital Universitario Dr. Jose E. Gonzalez, Ever Neuro Pharma GmbH | Ischemic Stroke, Acute, Diabetes Mellitus, Type 2, Blood Brain Barrier | 11/24 | 12/24 | | |
NCT04427241: Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness |
|
|
| Not yet recruiting | 4 | 12 | RoW | Cerebrolysin, Control | Konkuk University Medical Center, Ever Neuro Pharma GmbH | Disorder of Consciousness, Hemorrhagic Stroke | 07/25 | 12/25 | | |
